Chelator-Based Contrast Agents for Metal Ion Detection

Solution Overview

Problem

Current contrast agents for imaging techniques such as MRI, PET, CT, X-ray, SPECT, and ultrasound lack specificity and efficiency in detecting targets like zinc and human serum albumin in vivo, particularly in diagnostic and therapeutic applications.

Innovation Solution

Development of chelator groups with a target binding unit, capable of binding metal ions and proteins, generating detectable signals through changes in relaxometric, luminescent, or radioactive properties, using macrocycle structures with heteroatoms and specific metal ions like Gd3+, Eu3+, and In3+, and incorporating binding moieties like N,N′-bis-2-pyridyl methyl amine (BPMA) for enhanced signal generation and target interaction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional contrast agents are used for imaging, then imaging can be performed, but the agents lack specificity and efficiency in detecting targets like zinc and human serum albumin

Engineering Contradiction:
Core Design Contradiction:
Measurement precisionVSReliability

Solution Approach 1:

The contrast agent is divided into separate functional modules: a chelator group for metal ion binding, a binding moiety for target protein interaction, and a signal-generating unit. This segmentation allows each component to be optimized independently for its specific function, improving both specificity and efficiency of target detection

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention creates composite contrast agents by combining multiple functional units (chelator, binding moiety, signal generator) into a single molecular entity. This composite structure enables simultaneous metal ion chelation, target protein binding, and enhanced signal generation, resolving the contradiction between specificity and efficiency

Inventive Principle:
Principle #40Composite materials

2Measurement precision

If contrast agents bind to targets in vivo, then signal detection is enabled, but the agents require complex chelator groups with macrocycle structures and multiple heteroatoms

Engineering Contradiction:
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The chelator group is designed with macrocycle structures containing multiple heteroatoms that can coordinate with various metal ions (Gd3+, Eu3+, In3+, etc.), providing universal metal binding capability. This multi-functionality reduces the need for multiple different chelator designs, simplifying the overall approach despite the complex individual molecular structure

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The invention optimizes specific parameters of the chelator group (macrocycle ring size, heteroatom types and positions, substituent groups) to achieve optimal metal ion binding affinity and signal generation properties. By carefully tuning these parameters, high detection accuracy is achieved while avoiding unnecessary structural complexity

Inventive Principle:
Principle #35Parameter changes

3Reliability

If binding moieties like BPMA are incorporated for enhanced target interaction, then binding affinity increases, but the synthesis process becomes more complex requiring coupling agents and multiple steps

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The binding moiety (e.g., BPMA) is pre-synthesized as a separate, stable intermediate compound with defined structure and properties. This preliminary preparation allows for optimization of binding affinity independent of the chelator synthesis, and the pre-formed building block can be coupled to the chelator in a single definitive step, simplifying the overall manufacturing process despite the complexity of the final molecule

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The proposed solution enables precise detection and imaging of targets in vivo by altering signal properties upon binding, allowing for accurate localization and quantification of metal ions and proteins, even at low concentrations, facilitating diagnostic and therapeutic applications.

Implementation Method 1

a chelator group, a binding moiety covalently attached to the chelator group, wherein the binding moiety is capable of binding a target

Methodology Applied
Scientific EffectChelation: Chemical Bonding

Implementation Method 2

the metal ion can be at least one paramagnetic metal such as Gd3+, Eu3+, Tm3+, Dy3+, Tb3+, Yb3+, Mn2+

Methodology Applied
Scientific EffectParamagnetism: Magnetism

Implementation Method 3

For diagnostic by MRI Gd3+, Eu3+, Tm3+, Dy3+, Tb3+, Yb3+ and Mn2+ are preferred

Methodology Applied
Scientific EffectNuclear Magnetic Resonance: Magnetic Field

Implementation Method 4

A radioactive metal such as 111In3+, 113mIn3+, 67Ga3+, 68Ga3+, 99mTc4+, 64Cu2+, Tl3+, 153Sm3+, 166Ho3+ and 212Bi3+

Methodology Applied
Scientific EffectRadioactive decay: Radioactive Decay

Implementation Method 5

the binding moiety is capable of binding a target further binding a protein in vivo such as human serum albumin

Methodology Applied
Scientific EffectProtein binding: Adsorption

Data Source

PatentUS8679453B2Contrast agents
Publication Date: 2014.03.25
  • US8679453B2 patent drawing
  • US8679453B2 patent drawing
  • US8679453B2 patent drawing

AI summary

This invention includes agents and compositions having MRI, PET, CT, X-ray, SPECT or optical signals, and methods for their use in the determination of a target. In some cases, a MRI, PET, CT, X-ray, SPECT, optical or other signal produced by the agent or composition can be affected by the presence of the target. Examples of targets that can be determined by this invention include, but are not limited to zinc, copper, iron ions and other biological targets. Example of application for imaging in vivo includes the function of pancreas and other organs.